We read with great interest the article by Palazzuoli et al [1] , which briefly gives a clinical update on natriuretic peptides (NP). The authors describe the role of NP both in heart failure diagnosis and prognosis and in the acute coronary syndrome.
The authors report that repeated evaluation of NP carries prognostic information beyond a single measurement in different clinical settings, and, above all, repeated determinations of NT pro-BNP levels are relevant for the monitoring of disease progression [1] . However, we would remind everything that, in NP-guided outpatient treatment, the interpretation of NP levels must consider the variability of these peptides. Changes in the NP level below 50% may be in some patients within the range of biological variability and not representative of clinical events. The combination of symptoms, weight gain, and NP levels may be, therefore, probably the best way to make an early diagnosis of an episode of cardiac decompensation [2] .
In future perspectives and applications section, we would also add that biomarkers, such NP, might be used to predict a treatment response in settings other than heart failure (e.g., in management of atrial fibrillation, as a predictor of a successful cardioversion) [3] and that NP concentrations may be helpful in preoperative risk stratification (both cardiac and non cardiac surgery) [4] .
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